Current communication practices for biomarker testing in non-small cell lung cancer: Exploring patient and clinician perspectives

被引:2
|
作者
Pack, Allison [1 ,2 ,7 ]
Russell, Andrea [1 ,2 ]
Kircher, Sheetal [1 ,2 ]
Weldon, Christine [1 ,2 ,3 ,4 ]
Bailey, Stacy C. [1 ,2 ]
Lockwood, Karen [5 ]
Marquart, Tyler [5 ]
Afonso, Ana Sofia [6 ]
Payakachat, Nalin [5 ]
Wolf, Michael [1 ,2 ]
机构
[1] Northwestern Univ, Ctr Appl Hlth Res Aging, Feinberg Sch Med, Chicago, IL USA
[2] Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, Chicago, IL USA
[3] Northwestern Univ, Div Obstet & Gynecol, Feinberg Sch Med, Chicago, IL USA
[4] Ctr Business Models Healthcare, Glencoe, IL USA
[5] Eli Lilly & Co, Indianapolis, IN USA
[6] Eli Lilly BV, Utrecht, Netherlands
[7] Northwestern Univ, Div Gen Internal Med, Feinberg Sch Med, 750 N Lake Shore Dr, 10th Floor, Chicago, IL 60611 USA
基金
美国国家卫生研究院;
关键词
Non -small cell lung cancer; Patient education; Biomarker testing; LITERACY;
D O I
10.1016/j.pec.2023.107839
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objectives: We qualitatively explored patient and clinician experiences with biomarker testing in one academic health system to identify current communication practices and unmet testing information needs. Methods: We conducted 1:1 in-depth interviews with 15 clinicians (i.e., nurses, oncologists, pathologists) and 12 patients diagnosed with non-small cell lung cancer between January and May 2022. Participants described experiences with biomarker testing as well as associated communication practices and needs. Interviews were audio-recorded and transcribed. Analysis was informed by the Framework Method. Results: Patients described challenges retaining information early in their patient journey. While patients were generally aware of biomarkers and their effect on treatment options, they expressed limited knowledge of expected time delays between testing and receiving results. Additionally, many did not know their testing results. Clinicians and patients both noted no standard education material on biomarker testing is currently available. They suggested such materials could support patient knowledge and decision-making. Conclusions: Communication between patients and clinicians about biomarker testing is largely delivered through verbal counseling at a time when patients may be cognitively compromised. All participants supported the idea of delivering standard, tangible education materials on biomarker testing to patients. Practice implications: Education materials may enhance counseling efforts and patient knowledge.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] Australian Non-Small Cell Lung Cancer (NSCLC) Biomarker Testing Practices - A Survey of Medical Oncologists and Pathologists
    Gard, G.
    Kao, S.
    Solomon, B.
    Pavlakis, N.
    Cooper, W.
    Millward, M.
    Roberts-Thomson, R.
    Nott, L.
    Hughes, B.
    Hong, W.
    Dumas, M.
    Ramanujam, S.
    Wang, A.
    Elkouly, E.
    Gibbs, P.
    Markman, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S587 - S587
  • [22] Health Care Provider Practices and Perceptions of Biomarker Testing in US Veterans With Non-Small Cell Lung Cancer
    Vlachos, Elena
    Fox, Adam
    Dell'Italia, John
    Maurice, Nicholas
    Rubinstein, Israel
    Tanner, Nichole T.
    CHEST, 2025, 166 (02) : 630 - 635
  • [23] Current perspectives on the use of miRNA as a biomarker for EGFR-targeted therapy for non-small cell lung cancer
    Florczuk, Mateusz
    Szpechcinski, Adam
    Chorostowska-Wynimko, Joanna
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2017, 71 : 1207 - 1218
  • [24] Patient access to precision medicine: Identifying barriers to biomarker testing in non-small cell lung cancer.
    Levent, Ayse
    De Richter, Pieter
    Bender, Hope
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Olimetastatic disease: Current status and perspectives in non-small cell lung cancer
    Berghmans, T.
    Brandao, M.
    REVUE DES MALADIES RESPIRATOIRES, 2023, 40 (08) : 684 - 691
  • [26] Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
    Lim, Sun Min
    Hong, Min Hee
    Kim, Hye Ryun
    IMMUNE NETWORK, 2020, 20 (01)
  • [27] Disparities in biomarker testing practices in patients with metastatic non-small cell lung cancer (NSCLC) in the United States (US)
    Dennis, Michael J.
    Abrahami, Devin
    Vieira, Maria Cecilia
    Benjumea, Darrin
    Boyd, Marley
    Shao, Anran
    Duncan, Kirsten
    Kelton, John
    Patel, Sandip P.
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Biomarker utilization in non-small cell lung cancer, are we treating after testing?
    Makhoul, Elias
    Kim, Jong Taek
    Zhang, Wenjuan
    Lopategui, Jean Raphael
    Balmanoukian, Ani Sarkis
    Vail, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [29] The Importance of Biomarker Testing in the Treatment of Advanced Non-Small Cell Lung Cancer: A Podcast
    Hirsch, Fred R.
    Kim, Chul
    ONCOLOGY AND THERAPY, 2024, 12 (02) : 223 - 231
  • [30] Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer
    Sakamoto, Tomohiro
    Matsubara, Taichi
    Takahama, Takayuki
    Yokoyama, Toshihide
    Nakamura, Atsushi
    Tokito, Takaaki
    Okamoto, Tatsuro
    Akamatsu, Hiroaki
    Oki, Masahide
    Sato, Yuki
    Tobino, Kazunori
    Ikeda, Satoshi
    Mori, Masahide
    Mimura, Chihiro
    Maeno, Ken
    Miura, Satoru
    Harada, Toshiyuki
    Nishimura, Kunihiro
    Hiraoka, Manabu
    Kenmotsu, Hirotsugu
    Fujimoto, Junya
    Shimokawa, Mototsugu
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    JAMA NETWORK OPEN, 2023, 6 (12) : E2347700